Cue Energy Resources Aktie

Cue Biopharma reported a net loss of $5.2 million in Q1 2026 versus $12.3 million a year earlier, increased revenue to $5.7 million thanks to a collaboration with Boehringer Ingelheim, and cut R&D spending to $6.9 million. As of March 31 the company had $16.4 million in cash; after quarter-end it completed a private placement that raised about $30 million and also received a $7.5 million milestone payment. Cue plans IND filings for CUE-221 (expansion to food allergies) and CUE-401 (autoimmune diseases) in the second half of 2026 and appointed Dr. Shao-Lee Lin as president and CEO. » Más en de.investing.com

Cue Biopharma will implement a 1-for-30 reverse split effective Thursday at 5:00 p.m. ET; every 30 existing common shares will be combined into one new share and fractional shares will be paid in cash. Outstanding options and warrants and shares available under option plans will be adjusted proportionally, and trading on a split-adjusted basis is expected to begin Friday under the ticker CUE. The move is intended to satisfy the minimum bid requirement for listing on the Nasdaq Capital Market; the company also received a $7.5 million milestone payment from Boehringer Ingelheim and appointed Lucinda Warren as interim president and CEO. » Más en de.investing.com

At the Cantor Global Healthcare Conference, Cue Biopharma presented its strategic focus on T-cell modulation and reported pipeline progress, including CUE-401 for autoimmune diseases and the partner-developed CUE-501 with Boehringer Ingelheim. The company ended the quarter with $28 million in cash and an annual burn rate of about $25–28 million; additional funding is expected to come from partnerships and milestone payments. CUE-101 showed significant survival benefits in oncology studies both alone and in combination with Keytruda, and a positive pre‑IND meeting with the FDA paves the way for an IND submission for CUE-401 in June 2026. Several preclinical milestones for CUE-401 and CUE-501 are expected over the next 12–18 months. » Más en de.investing.com